UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, ...

Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company announced today that the New England Journal of Medicine (NEJM) published results of the 204-patient, global, ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodi ...

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a ...

A 41-year-old man was evaluated for swelling in the ankles and syncope. CT of the chest showed bilateral mediastinal and ...

In Utah, patients who consent to "hormonal transgender treatment" or surgery on "sex characteristics" while they are minors ...

Under the Health Care Malpractice Act, updated in 2023, minors can recant their consent before age 25 if they develop a “permanent injury” from their treatment, with the argument that their doctor ...

For over 200 years, the New England Journal of Medicine (NEJM) has brought important medical news to the world’s most influential physicians. The global medical community, physicians ...

Scientists have discovered three powerful new drug regimens that offer more effective treatment for tuberculosis—bringing ...

The research, published Jan. 30 in the New England Journal of Medicine, was led by researchers at Harvard Medical School and other members of the endTB project, a collaboration among Partners In ...

Tirzepatide is a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors that results in 12 to 21% weight loss in patients with obesity; however ...

The blood pressure study could help doctors treating people with diabetes to reduce the risk of "major cardiovascular events" ...